CHGCF:OTC-Chugai Pharmaceutical Co., Ltd (USD)

COMMON STOCK | Drug Manufacturers—General |

Last Closing

USD 105

Change

0.00 (0.00)%

Market Cap

USD 63.39B

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-04-08 )

Largest Industry Peers for Drug Manufacturers—General

ETFs Containing CHGCF

1638:TSE 6.85 % 0.00 %

N/A

N/A
JPMV:PA 2.60 % 0.00 %

N/A

N/A
OSXJ:XETRA 2.60 % 0.00 %

N/A

N/A
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.69 %

-0.09 (0%)

CAD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers—General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 63.93% 100% F 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.93% 100% F 92% A
Trailing 12 Months  
Capital Gain 58.47% 97% N/A 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.47% 91% A- 89% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 17.97% 83% B 63% D
Dividend Return 17.97% 78% C+ 61% D-
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 22.09% 56% F 80% B-
Risk Adjusted Return 81.35% 86% B+ 93% A
Market Capitalization 63.39B 77% C+ 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.